Embecta (EMBC) to Release Earnings on Thursday

Embecta (NASDAQ:EMBC) is projected to announce its Q1 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $0.67 per share and revenue of $258.0660 million for the quarter. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Tuesday, November 25th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.04. The business had revenue of $263.30 million for the quarter, compared to analysts’ expectations of $265.66 million. Embecta had a negative return on equity of 24.62% and a net margin of 8.83%.The firm’s quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.45 EPS. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Trading Up 3.1%

Embecta stock opened at $10.94 on Tuesday. Embecta has a 12 month low of $9.20 and a 12 month high of $18.58. The stock has a fifty day simple moving average of $11.92 and a two-hundred day simple moving average of $12.97. The firm has a market cap of $647.76 million, a price-to-earnings ratio of 6.71 and a beta of 1.11.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Friday, December 5th were issued a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 5.5%. The ex-dividend date was Friday, December 5th. Embecta’s dividend payout ratio (DPR) is presently 36.81%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EMBC. BTIG Research restated a “buy” rating on shares of Embecta in a research note on Tuesday, November 25th. Zacks Research downgraded shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $18.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in EMBC. Larson Financial Group LLC increased its stake in shares of Embecta by 368.6% in the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after buying an additional 6,224 shares in the last quarter. Wexford Capital LP purchased a new stake in Embecta in the third quarter worth about $94,000. Humankind Investments LLC bought a new position in shares of Embecta in the second quarter worth about $111,000. Finally, iSAM Funds UK Ltd purchased a new position in shares of Embecta during the 3rd quarter valued at about $115,000. 93.83% of the stock is currently owned by institutional investors.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.